Get started
EDWARDS LIFESCIENCEDWARDS LIFESCIENCEDWARDS LIFESCIENC

EDWARDS LIFESCIENC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

EWL chart


Full chart

EWL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪35.99 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
54.572
Basic EPS (TTM)
1.328 CHF
Net income (FY)
‪794.31 M‬ CHF
Revenue (FY)
‪4.94 B‬ CHF
Shares float
‪574.69 M‬
Beta (1Y)
0.64

Employees


Employees (FY)
‪15.8 K‬
Change (1Y)
‪−4 K‬ −20.20%
Revenue / Employee (1Y)
‪312.67 K‬ CHF
Net income / Employee (1Y)
‪80.53 K‬ CHF

About Edwards Lifesciences Corporation


Sector
Health Technology
Industry
Medical Specialties
CEO
Bernard J. Zovighian
Website
edwards.com
Headquarters
Irvine
Founded
1958
FIGI
BBG00C5YWSN1
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Check out other big names from the same industry as EWL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EWL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

EWL highest yielding bonds


US28176EAD0
EDWARDS LIFE. 18/28
Yield to maturity
4.42%
Maturity date
Jun 15, 2028

See all EWL bonds 

Frequently Asked Questions


The current price of EWL is 61.188 CHF — it has decreased by −6.99% in the past 24 hours. Watch EDWARDS LIFESCIENC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange EDWARDS LIFESCIENC stocks are traded under the ticker EWL.
We've gathered analysts' opinions on EDWARDS LIFESCIENC future price: according to them, EWL price has a max estimate of 87.52 CHF and a min estimate of 48.98 CHF. Watch EWL chart and read a more detailed EDWARDS LIFESCIENC stock forecast: see what analysts think of EDWARDS LIFESCIENC and suggest that you do with its stocks.
EWL reached its all-time high on Apr 22, 2022 with the price of 119.985 CHF, and its all-time low was 58.252 CHF and was reached on Nov 11, 2024. View more price dynamics on EWL chart.
See other stocks reaching their highest and lowest prices.
EWL stock is 7.52% volatile and has beta coefficient of 0.64. Track EDWARDS LIFESCIENC stock price on the chart and check out the list of the most volatile stocks — is EDWARDS LIFESCIENC there?
Today EDWARDS LIFESCIENC has the market capitalization of ‪36.14 B‬, it has increased by 0.19% over the last week.
Yes, you can track EDWARDS LIFESCIENC financials in yearly and quarterly reports right on TradingView.
EDWARDS LIFESCIENC is going to release the next earnings report on Jul 24, 2025. Keep track of upcoming events with our Earnings Calendar.
EWL earnings for the last quarter are 0.57 CHF per share, whereas the estimation was 0.53 CHF resulting in a 7.30% surprise. The estimated earnings for the next quarter are 0.49 CHF per share. See more details about EDWARDS LIFESCIENC earnings.
EDWARDS LIFESCIENC revenue for the last quarter amounts to ‪1.25 B‬ CHF, despite the estimated figure of ‪1.24 B‬ CHF. In the next quarter, revenue is expected to reach ‪1.18 B‬ CHF.
EWL net income for the last quarter is ‪323.29 M‬ CHF, while the quarter before that showed ‪350.20 M‬ CHF of net income which accounts for −7.68% change. Track more EDWARDS LIFESCIENC financial stats to get the full picture.
No, EWL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 19, 2025, the company has ‪15.8 K‬ employees. See our rating of the largest employees — is EDWARDS LIFESCIENC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EDWARDS LIFESCIENC EBITDA is ‪1.46 B‬ CHF, and current EBITDA margin is 29.41%. See more stats in EDWARDS LIFESCIENC financial statements.
Like other stocks, EWL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EDWARDS LIFESCIENC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EDWARDS LIFESCIENC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EDWARDS LIFESCIENC stock shows the strong sell signal. See more of EDWARDS LIFESCIENC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.